PharVision Advisers’s MasTec MTZ Stock Holding History

PharVision Advisers’s Portfolio MTZ Stock Details MTZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,642	Closed	-$224K	–	434
2024 Q4	$224K	Buy	+1,642	New	+$220K	0.19%	258

Other funds holding MTZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCC

Hill City Capital Boston, Massachusetts $2.8B AUM 79.27% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PharVision Advisers's MTZ Position: Q1 2025 in Review

PharVision Advisers sold out of MasTec (MTZ) in Q1 2025, closing a stake of 1,642 shares — an estimated $224K sold.

PharVision Advisers first reported a position in MTZ in Q4 2024 and held it in 1 quarter. The position peaked at $224K in Q4 2024. 523 funds tracked by Wall St. Rank hold MTZ as of Q1 2025.

PharVision Advisers reported no remaining MasTec position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 1,642 MasTec shares in Q1 2025, an estimated $224K.
PharVision Advisers first reported a position in MasTec in Q4 2024 and held it in 1 quarter.
PharVision Advisers's MasTec position peaked at $224K in Q4 2024.
523 funds tracked by Wall St. Rank held MasTec as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.